---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-008116"
form_type: "8-K"
ticker: "KAPA"
cik: "0001962011"
company_name: "Kairos Pharma, LTD."
filed_at: "2026-02-26T23:59:59+00:00"
generated_at: "2026-05-15T23:49:29.412085+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Kairos Pharma signs term sheet to acquire two lung cancer assets from Celyn Therapeutics

## Summary
- Worldwide rights to CL-273 (pre-IND pan-EGFR inhibitor) and CL-741 (Phase 1-ready c-MET inhibitor) for NSCLC.
- No financial terms or expected close date disclosed in press release or filing.
- CL-273 is wild-type-sparing with 4-5x wider safety margin; CL-741 targets MET-amplification resistance.
- Celyn backed by OrbiMed and Torrey Pines Investment; Kairos plans to use Cedars-Sinai clinical network.
- Acquisition aims to address EGFR-mutant and c-MET-driven lung cancer resistance mechanisms.

## SEC filing metadata
- accession: 0001493152-26-008116
- form_type: 8-K
- ticker: KAPA
- cik: 0001962011
- company_name: Kairos Pharma, LTD.
- filed_at: 2026-02-26T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1962011/000149315226008116/0001493152-26-008116-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1962011/000149315226008116/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-008116
- JSON: https://secwatch.observer/filing/0001493152-26-008116.json
- Plain text: https://secwatch.observer/filing/0001493152-26-008116.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.